Glyscend in the news
Press releases
Glyscend Therapeutics Appoints Sapan A. Shah, Ph.D., Accomplished Industry Executive, as Chief Executive Officer
Boston, MA (September 5, 2023) – Glyscend Therapeutics… today announced the appointment of Sapan Shah, Ph.D., as Chief Executive Officer. Dr. Shah has more than 25 years of experience leading innovative life science companies as CEO, founder, board member and strategic advisor. His appointment is part of a planned leadership transition to accelerate Glyscend’s growth as it further advances lead product candidate, GLY-200, a clinical stage oral polymer medicine targeting gut mediated metabolic signaling.
Press Release | July 27, 2023
Glyscend Therapeutics Announces Publication of GLY-200 First-in-Human Data and Availability of Phase 2a Clinical Results
Boston, MA (July 27, 2023) – Glyscend Therapeutics… today announced that safety and pharmacodynamic data from the first-in-human Phase 1 trial of GLY-200 were published in Diabetes, Obesity and Metabolism. The data published demonstrate that GLY-200, the company’s lead clinical candidate, mimics the biomarker signature seen with metabolic surgery and appeared to be safe and generally well-tolerated.
Press Release | May 31, 2023
Glyscend Therapeutics Announces Positive Topline Phase 2a Clinical Results and Progress with GLY-200, a First-in-Class Treatment for Type 2 Diabetes and Obesity
Boston, MA (May 31, 2023) – Glyscend Therapeutics…today announced clinical progress with its lead candidate, GLY-200, for the treatment of type 2 diabetes (T2D) and obesity. Data across completed Phase 1 and Phase 2a clinical trials demonstrated that the novel mechanism of GLY-200 offers significant and clinically relevant reductions in postprandial glucose and body weight and support its advancement into a Phase 2b clinical trial.
Press Release | March 30, 2023
Glyscend Therapeutics Appoints Biotech Industry Veteran Michael Wyzga to its Board of Directors
Boston, MA (March 30, 2023) – Glyscend Therapeutics, a clinical-stage biotechnology company pioneering a new generation of orally administered polymer therapies, today announced the appointment of Michael Wyzga to its Board of Directors. Mr. Wyzga brings over two decades of deep experience leading and advising life sciences companies to the Glyscend Board.
Press Release | September 20, 2022
Glyscend Therapeutics Releases New Phase 1 Biomarker Results and Initiates Phase 2 Clinical Trial under an IND for GLY-200 as a Potential First-in-Class Type 2 Diabetes Treatment
Boston, MA (September 20, 2022) – Glyscend Therapeutics , a clinical-stage biotechnology company, today reported additional biomarker results from their Phase 1 study of GLY-200, a proprietary orally administered, gut-restricted therapeutic for the treatment of type 2 diabetes (T2D). Glyscend also received clearance from the U.S. Food and Drug Administration (FDA) on an Investigational New Drug (IND) application to…
Press Release | May 11, 2022
Glyscend Therapeutics Announces Completion of Phase 1 Clinical Trial of its Oral, Gut-restricted, Polymer Therapeutic, GLY-200, as a Potential Type 2 Diabetes Treatment
Boston, MA and Baltimore, MD (May 11, 2022) – Glyscend reported the completion of a Phase 1 trial for its lead clinical-stage program, GLY-200, as a treatment for type 2 diabetes (T2D). In addition, Glyscend announced the expansion of its leadership team with the appointment of Mark Fineman, Ph.D., a seasoned R&D leader in metabolic diseases, as Chief Development Officer…
Press Release | September 28, 2021
Glyscend Therapeutics Announces Initiation of Phase 1 Clinical Trial on the Heels of Preclinical Data Presented at EASD 2021 on the Metabolic Benefits of its Oral Polymer-based Duodenal Exclusion Therapy
Boston, MA and Baltimore, MD (September 28, 2021) – Phase 1 clinical trial currently underway in Australia investigating a noninvasive, oral polymer therapy that dramatically improves glucose homeostasis with weight loss in nonclinical models…
Press Release | August 04, 2021
Glyscend Therapeutics Announces Preclinical Data at ADA 2021 on the Metabolic Benefits of its Oral Polymer-based Duodenal Exclusion Therapy
Baltimore, MD (August 04, 2021) – Glyscend Inc presented data during the American Diabetes Association 80th Scientific Sessions virtual meeting, June 25-29, 2021, from a study of its proprietary oral polymer duodenal exclusion therapy. The positive data were presented ahead of Glyscend’s phase I clinical trials, which have commenced recruiting healthy subjects in South Australia…
Press Release | June 11, 2020
Glyscend Therapeutics Completes $20.5M Financing Round to Advance Novel Oral Polymer Therapy for Type 2 Diabetes
Baltimore, MD (June 11, 2020) – Glyscend Therapeutics, a privately held biopharmaceutical company developing novel treatments for type 2 diabetes (T2D) and related metabolic conditions, today announced the closing of a $20.5 million Series A financing round…
News features
BioTuesdays | September 5, 2023
Glyscend pioneering new class of GI-targeted therapy for T2D and obesity
Closely-held Glyscend Therapeutics is developing an orally administered, gut-restricted drug for Type 2 diabetes and obesity, based on “duodenal exclusion” physiology, a key mechanism of gastric bypass surgery.
Endpoints News | May 31, 2023
Glyscend Therapeutics' early data show polymer mimics benefits of surgery in type 2 diabetes, obesity
Glyscend Therapeutics released topline data for its polymer targeting type 2 diabetes and obesity today, with the hopes the candidate will have the same effects as bariatric surgery without complications from the invasive standard-of-care procedures.
BioSpace | May 31, 2023
Glyscend’s First-in-Class Oral Diabetes Drug Shows Phase II Promise
Top-line results from a Phase IIa study showed that Glyscend Therapeutics’ lead candidate GLY-200 demonstrated promising safety and efficacy in patients with Type 2 diabetes, the company announced Wednesday.
Nature’s Biopharma Dealmakers | June 2022
Pharmacologic duodenal exclusion: a novel therapy for metabolic diseases
Glyscend Therapeutics is developing first-in-class polymer drugs that uniquely interact with the gut wall to treat metabolic and chronic conditions. The company’s lead candidate, GLY-200, is advancing into phase 2 clinical studies for the treatment of type 2 diabetes…
Scientific American’s Next Frontiers | January 2018
A treatment that’s easier to stomach (p. 6-7)
What if there were a cure for type 2 diabetes, but most patients couldn’t benefit from it? This simple question inspired Ashish Nimgaonkar, a gastroenterologist at Johns Hopkins University, and his colleagues at the Center for Bioengineering Innovation and Design to found Glyscend…
TedCo | May 2017
Glyscend wins TEDCO's 2017 ICE Award for Innovation in Baltimore
The Maryland Technology Development Corporation (TEDCO) today hosted the organization’s seventh annual ICE Awards. Held at the Columbus Center (IMET) in Baltimore, Md., the awards program recognized outstanding businesses and individuals from TEDCO’s diverse portfolio of more than 300 seed and early-stage companies…
Johnson-Johnson | January 2017
3 Entrepreneurs, 3 Big Ideas: Cutting-Edge Cancer, Alzheimer's and Diabetes Research
They share one thing in common: a goal of transforming the way illnesses are treated in the most forward-thinking way possible. Meet three innovators whose ideas could someday change the future of healthcare….
Baltimore Business Journal | November 2016
Baltimore startup wins $500,000 grant from Johnson & Johnson
Baltimore-based Glyscend Inc. was awarded one of three $500,000 research grants from Johnson & Johnson Innovation LLC and its research arm Janssen as part of the health care giant’s World Without Disease QuickFire Challenge…
Glu | October 2016
Glyscend places 2nd in the T1D Exchange/M2D2 Diabetes Innovation Challenge in Boston, MA.
The excitement around the Diabetes Innovation Challenge continued last week, as T1D Exchange and M2D2 hosted the second of two Semi-finals events at the University of Massachusetts Lowell Student Center…
Hopkins Biotech Network | April 2016
Glyscend featured in Hopkins Biotech Network's Alumni Spotlight.
Which division of the University did you all graduate from? Whiting School of Engineering, Department of Biomedical Engineering, Center for Bioengineering Innovation & Design…
Center for Bioengineering Innovation & Design | September 2015
Three CBID Alums Form Start-up With Goal of Disrupting Landscape of T2DM.
T2DM is one of the most prevalent diseases in the United States, with over 20 million diagnosed patients, approximately 8 million undiagnosed, and an additional 86 million with the condition known as prediabetes.
SBIR / STTR | September 2015
Glyscend presents at the NSF SBIR/STTR Phase I Conference in Arlington, VA
National Scientific Foundation (NSF) | July 2015
Glyscend wins $225,000 NSF STTR Grant in partnership with Johns Hopkins University
The broader impact/commercial potential of this Small Business Technology Transfer (STTR) Phase I project is to develop the first non-invasive, device-based treatment for type 2 diabetes which mimics the therapeutic benefits of bariatric surgery…